Olema Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. (ticker: OLMA) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. For French-speaking investors, Olema is best understood as a clinical-stage oncology story: the company does not yet rely on broad commercial product sales, and its valuation is primarily driven by clinical execution, scientific differentiation, pipeline optionality, and eventual regulatory and partnership outcomes. Founded in 2006 under the original name CombiThera, Inc., Olema is headquartered in San Francisco, California, and also maintains operations in Cambridge, Massachusetts. Olema’s business focus is highly specialized. The company is centered on oncology, with a particular emphasis on metastatic breast cancer and, more broadly, endocrine-driven cancers. Its research and development strategy leverages a deep understanding of nuclear receptors, hormone-dependent tumor biology, and mechanisms of acquired resistance. The company’s lead asset is palazestrant, a next-generation endocrine therapy being advanced across multiple settings, including combination regimens and monotherapy. Olema is running two important Phase 3 studies, OPERA-01 and OPERA-02, which makes the company a significant clinical-stage participant in the breast-cancer treatment landscape. In parallel, Olema is also developing OP-3136, a KAT6 inhibitor in early-stage clinical development, which broadens the pipeline beyond a single asset and potentially beyond a single indication. From a competitive standpoint, Olema operates in a crowded and scientifically demanding segment of the biopharmaceutical industry. It competes against larger pharmaceutical companies and specialized oncology biotechs focused on HR+/HER2- breast cancer and related endocrine pathways. Olema’s key differentiation lies in its focused scientific platform, its pipeline depth, and its strategy of pairing proprietary assets with standard-of-care agents to improve outcomes. A notable example of this approach is the clinical collaboration with Novartis for the OPERA-02 study, where ribociclib supply supports the combination trial design. That partnership underscores Olema’s ability to work with established oncology players to accelerate data generation and potentially strengthen future commercialization pathways. Recent milestones have been material. In 2026, Olema reported ongoing execution across OPERA-01 and OPERA-02 and indicated first clinical data for OP-3136 would be presented at ASCO. The company also executed a public equity offering in 2025, improving its financial runway for clinical development. For investors monitoring SEC Form 4 insider transactions, Olema is also a name where insider activity can attract attention because it may signal management confidence, equity-based compensation activity, or portfolio adjustments. Overall, Olema Pharmaceuticals remains a higher-risk, high-upside U.S. biotech name whose medium-term investment case depends on clinical success, regulatory progress, and the strength of strategic partnerships.